Docetaxel (Taxotere): preclinical and general clinical information.
Docetaxel (Taxotere; Rhône-Poulenc Rorer, Collegeville, PA) is the second member of the taxane class of cytotoxic agents to reach clinical use. The development of docetaxel was remarkably rapid, from the initial hemisynthesis in 1986 to worldwide filing for commercial use in 1994. Docetaxel is now approved in over 90 countries. As the use of docetaxel expands as a result of continuing preclinical and clinical investigation, better strategies for treatment of patients with cancer are emerging. This report reviews certain important new developments regarding docetaxel involving both its pharmacology and use in practice.
Earhart
R H
RH
Oncology Medical Affairs, Rhône-Poulenc Rorer Pharmaceuticals, Inc, Collegeville, PA 19426, USA.
D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids
D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel